STOCK TITAN

Director at Tango Therapeutics (TNGX) receives RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tango Therapeutics director Robert Azelby reported equity awards from the company. He received 5,740 shares of Common Stock in the form of restricted stock units (RSUs), with each RSU representing one future share.

The RSUs will vest in three substantially equal annual installments following the grant date, as long as he remains in continuous service. He was also granted a stock option covering 35,910 shares of Common Stock at an exercise price of $27.97 per share. This option vests in 36 substantially equal monthly installments over three years, subject to continued service, and expires on June 19, 2036. These are compensation-related grants, not open‑market purchases.

Positive

  • None.

Negative

  • None.
Insider Azelby Robert
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 35,910 $0.00 --
Grant/Award Common Stock 5,740 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 35,910 shares (Direct, null); Common Stock — 5,740 shares (Direct, null)
Footnotes (1)
  1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
RSU grant 5,740 shares Restricted stock units awarded to director as of June 19, 2026
Option grant size 35,910 shares Stock option covering Common Stock granted to director
Option exercise price $27.97 per share Exercise price for 35,910-share stock option
Option expiration June 19, 2036 Expiration date of stock option grant
RSUs after grant 5,740 shares Total Common Stock represented by RSUs following transaction
Options after grant 35,910 options Total stock options held from this grant following transaction
restricted stock units financial
"These shares are represented by restricted stock units (the "RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of $27.9700."
vest financial
"The RSUs will vest in three substantially equal annual installments following the grant date."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price": "27.9700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-06-19T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Azelby Robert

(Last)(First)(Middle)
C/O TANGO THERAPEUTICS, INC.
201 BROOKLINE AVE., SUITE 901

(Street)
BOSTON MASSACHUSETTS 02215

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/19/2026A5,740(1)A$05,740D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$27.9706/19/2026A35,910 (2)06/19/2036Common Stock35,910$035,910D
Explanation of Responses:
1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
2. This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
/s/ Julie Fogarty, as attorney-in-fact06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tango Therapeutics (TNGX) director Robert Azelby receive in this Form 4?

Robert Azelby received equity compensation from Tango Therapeutics, including 5,740 restricted stock units and a stock option for 35,910 shares. These awards are grants from the company, not open-market purchases, and are tied to his ongoing service as a director.

How do the 5,740 RSUs granted to Tango Therapeutics (TNGX) director vest?

The 5,740 RSUs vest in three substantially equal annual installments after the grant date. Each vesting installment requires Robert Azelby to remain in continuous service with Tango Therapeutics through the applicable vesting date to receive the underlying Common Stock shares.

What are the key terms of the 35,910-share stock option granted by Tango Therapeutics (TNGX)?

The stock option covers 35,910 shares of Common Stock at an exercise price of $27.97 per share. It vests in 36 substantially equal monthly installments over three years, conditioned on continuous service, and is scheduled to expire on June 19, 2036 if not exercised.

Is the Tango Therapeutics (TNGX) Form 4 for a stock purchase or a compensation grant?

The Form 4 reflects compensation-related equity grants, not an open-market stock purchase. Robert Azelby received RSUs and a stock option as awards from Tango Therapeutics, with vesting schedules tied to his continued service rather than immediate cash transactions in the market.

What is the exercise price and expiration date of the Tango Therapeutics (TNGX) option grant?

The option granted to Robert Azelby has an exercise price of $27.97 per share and an expiration date of June 19, 2036. He may exercise vested portions before expiration, subject to plan terms and his continued service with Tango Therapeutics.